황반변성증 치료 시장 보고서 : 유형, 병기, 투여 경로, 최종사용자, 지역별(2026-2034년)

The global macular degeneration treatment market size reached USD 10.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 16.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.87% during 2026-2034. The market is majorly driven by the increasing incidences of age-related macular degeneration and obesity among the masses, growing prevalence of sedentary lifestyles, rapid utilization of smart devices, and significant improvements in the healthcare infrastructure, particularly in developing economies.

MACULAR DEGENERATION TREATMENT MARKET ANALYSIS:

• Major Market Drivers: The increasing prevalence of macular degeneration, especially among the aging population, is a primary market driver. Advances in diagnostic techniques and treatment modalities are also contributing significantly. Rising awareness and early diagnosis initiatives further fuel the market expansion.
• Key Market Trends: There is a notable shift towards biologics and gene therapy in the treatment of macular degeneration. Minimally invasive procedures and innovative drug delivery systems are gaining traction. Personalized medicine and tailored treatment approaches are becoming increasingly prevalent. This, in turn, is creating a positive macular degeneration treatment market overview.
• Geographical Trends: North America leads the market due to high healthcare spending and advanced medical infrastructure. Europe also shows substantial growth owing to increased research funding and an aging population. Asia-Pacific is further emerging as a lucrative market due to rising healthcare investments and a growing patient pool.
• Competitive Landscape: Some of the key market players include Alcon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma US, Inc., Bausch + Lomb, Bayer Consumer Care AG, F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc., Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Samsung Bioepis.
• Challenges and Opportunities: High treatment costs and limited access to advanced therapies pose significant challenges in the market. However, ongoing research and development present opportunities for novel treatments. Expansion into emerging markets and technological advancements in treatment methods offer potential for future growth.

MACULAR DEGENERATION TREATMENT MARKET TRENDS:

Increasing research and development (R&D) activities

Extensive R&D efforts are being focused on creating medications that target specific biochemical pathways involved in macular degeneration, such as anti-VEGF therapies that prevent aberrant blood vessel formation. These medications not only improve visual outcomes, but they also increase treatment intervals, which improves patient convenience and compliance. Furthermore, technical advancements like as sustained-release drug delivery systems and gene therapy provide great promise for long-term management and potential solutions. Collaboration among academics, pharmaceutical corporations, and biotech enterprises creates a fertile ground for breakthroughs, thereby bolstering the macular degeneration treatment market outlook.

Growing burden of retinal disorders

The rising prevalence of retinal illnesses is contributing to the market expansion. For example, according to a research article published in the British Journal of Ophthalmology in August 2020, age-related macular degeneration (AMD) is the leading cause of vision impairment and blindness in Europe. Age-related macular degeneration (AMD) affects around 67 million people in Europe, and this figure is anticipated to rise by 15% by 2050 as the population ages. According to data, the growing number of people suffering from retinal problems correlates closely with the market growth. Thus, the rising prevalence of such conditions is driving the market during the macular degeneration treatment market forecast period.

Rising geriatric population

The growing geriatric population around the world is likely to drive the global market over the forecast period. The prevalence of retinal diseases rises with age. AMD is the most common cause of blindness in developed countries, especially among individuals over the age of sixty. According to the World Health Organization (WHO), in 2019, the number of people aged 60 years and older was 1 billion. This is expected to create a positive outlook for the market and increase the macular degeneration treatment market revenue.

MACULAR DEGENERATION TREATMENT MARKET SEGMENTATION:

Breakup by Type:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Wet age-related macular degeneration dominates the market

The global macular degeneration treatment market report shows that wet age-related macular degeneration category dominated the global market. Wet AMD is treated with intravitreal injections (IVT), and an estimated 22.3 million operations were performed worldwide in 2017. Approximately 75% of anti-VEGF injections were administered to treat wet AMD. The effectiveness of these treatments, combined with advances in diagnostic technologies, continues to enhance access and therapeutic outcomes for patients suffering from wet AMD. The high prevalence of the condition, branded drugs, more awareness, and an increase in the number of therapies for wet AMD are all contributing to the segment's dominance in the macular degeneration treatment market share.

Breakup by Stage of Disease:

• Early Stage
• Intermediate Stage
• Late Stage

Late stage holds the largest share in the market

The late stage of macular degeneration has a substantial impact on the market. As the disorder progresses, individuals experience severe vision impairment. The necessity to treat this illness fuels research and interest in these treatments. Pharmaceutical corporations are motivated to develop drugs and treatments, resulting in more advanced treatment options. Furthermore, given the critical need for treatments in the late stages of the illness, medical professionals and patients are more willing to accept novel therapy, regardless of cost. This dynamic supports macular degeneration treatment market growth and advancement for these treatments.

Breakup by Route of Administration:

• Intravenous Route
• Intravitreal Route

Intravitreal route holds the maximum share in the market

The intravitreal route is a critical driver in the market. This strategy considers designated treatment, lessening fundamental secondary effects, and working on quiet results. The rising prevalence of age-related macular degeneration and diabetic retinopathy enhances the interest in intravitreal routes. Headways in drug plans and conveyance procedures further improve the allure of this route. Furthermore, the intravitreal administration's demonstrated adequacy in clinical trials upholds its adoption by ophthalmologists, thus fueling the macular degeneration treatment demand.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Center
• Others

Hospitals hold the maximum share in the market

Hospitals play an important role in providing a boost to the market. Their excellent diagnostic capabilities and specialized care facilities appeal to patients seeking complete eye care. They also provide a platform for the implementation of cutting-edge technologies and therapies, which improve patient outcomes. Collaboration between hospitals and pharmaceutical companies speeds up the development of new medications and treatment methods. Furthermore, the emphasis on quality care and patient management in hospitals increases demand for effective macular degeneration therapies, which contributes significantly to market expansion.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest macular degeneration treatment market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for macular degeneration treatment.

North America dominated the market with the highest revenue share and the presence of a large number of major macular degeneration treatment companies. This dominance can be attributed to the rising prevalence of AMD. According to the American Academy of Ophthalmology, around 15 million individuals in North American live with AMD. There is also a high prevalence of macular degeneration in the region, which is expected to rise in the coming years. Furthermore, the growing geriatric population and disease burden are also propelling the market. The favorable government initiatives to support the affordability of costly anti-VEGF products are expected to contribute to the market growth.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Alcon Inc.
• Apellis Pharmaceuticals, Inc.
• Astellas Pharma US, Inc.
• Bausch + Lomb
• Bayer Consumer Care AG
• F. Hoffmann-La Roche Ltd
• Novartis Pharmaceuticals Corporation
• Ocular Therapeutix, Inc.
• Regeneron Pharmaceuticals Inc.
• Regenxbio Inc.
• Samsung Bioepis

Frequent approvals and launches of novel medications by key players are resulting in macular degeneration treatment market recent developments. Increased investments in R&D are pivotal for the development of effective treatments. Notably, companies are investing in genetic medicines and the development of novel drugs such as anti-VEGF (Vascular Endothelial Growth Factor) therapies. For example, in October 2021, Roche announced that the Food and Drug Administration (FDA) had approved Susvimo (100 mg/mL ranibizumab injection) to treat wet, or neovascular, age-related macular degeneration (AMD), a disease that can cause rapid and severe vision loss. Also, there's a notable trend of mergers, acquisitions, and partnerships among key players aiming to consolidate market presence and enhance their product portfolios. Companies are also focusing on expanding their reach in high-growth regions such as Asia-Pacific, where the increasing geriatric population and government initiatives to improve healthcare accessibility is favorably impacting the market. Apart from this, some of the macular degeneration treatment market recent opportunities include leveraging state-of-the-art technologies for enhancing patient outcome by various major players and the introduction of AI-powered imaging and analytics for improving the accuracy of diagnoses and enabling personalized treatment plans.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Macular Degeneration Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Dry Age-related Macular Degeneration
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Wet Age-related Macular Degeneration
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Stage of Disease

• 7.1 Early Stage
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Intermediate Stage
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Late Stage
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Intravenous Route
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Intravitreal Route
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Ambulatory Surgical Center
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Alcon Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Apellis Pharmaceuticals, Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Astellas Pharma US, Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Bausch + Lomb
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Bayer Consumer Care AG
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 F. Hoffmann-La Roche Ltd
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Novartis Pharmaceuticals Corporation
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Ocular Therapeutix, Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Regeneron Pharmaceuticals Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Regenxbio Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Samsung Bioepis
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis